Lisa Wang

8.2k total citations
191 papers, 5.1k citations indexed

About

Lisa Wang is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Lisa Wang has authored 191 papers receiving a total of 5.1k indexed citations (citations by other indexed papers that have themselves been cited), including 81 papers in Oncology, 70 papers in Pulmonary and Respiratory Medicine and 46 papers in Molecular Biology. Recurrent topics in Lisa Wang's work include Ovarian cancer diagnosis and treatment (32 papers), Cancer Genomics and Diagnostics (27 papers) and Lung Cancer Treatments and Mutations (22 papers). Lisa Wang is often cited by papers focused on Ovarian cancer diagnosis and treatment (32 papers), Cancer Genomics and Diagnostics (27 papers) and Lung Cancer Treatments and Mutations (22 papers). Lisa Wang collaborates with scholars based in Canada, United States and Australia. Lisa Wang's co-authors include Amit M. Oza, Ian F. Tannock, Monika K. Krzyzanowska, Lillian L. Siu, K. Barry Sharpless, David L. Morris, Mohammad H. Pourgholami, Margaret Kolb, Eric X. Chen and Malcolm J. Moore and has published in prestigious journals such as Journal of the American Chemical Society, Nature Medicine and Nature Communications.

In The Last Decade

Lisa Wang

178 papers receiving 5.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lisa Wang Canada 42 1.8k 1.7k 1.2k 647 611 191 5.1k
Ali Shamseddine Lebanon 39 2.3k 1.3× 1.6k 1.0× 1.1k 0.9× 1.1k 1.7× 965 1.6× 249 5.6k
Ondřej Topolčan Czechia 31 1.6k 0.9× 1.3k 0.8× 1.0k 0.9× 1.1k 1.7× 622 1.0× 254 4.2k
David S. Mendelson United States 41 2.0k 1.1× 2.5k 1.4× 2.0k 1.7× 652 1.0× 709 1.2× 188 7.1k
Teresa A. Goldin United States 4 1.9k 1.0× 2.1k 1.2× 1.2k 1.0× 1.3k 2.0× 730 1.2× 5 4.7k
Madappa N. Kundranda United States 16 2.4k 1.3× 2.5k 1.5× 1.4k 1.2× 1.5k 2.4× 901 1.5× 66 5.8k
Recinda Sherman United States 29 3.2k 1.7× 1.4k 0.8× 1.4k 1.2× 1.2k 1.8× 645 1.1× 58 6.8k
Francesco Perrone Italy 38 3.6k 2.0× 1.1k 0.6× 1.8k 1.5× 870 1.3× 567 0.9× 188 5.9k
Stefano Rosso Italy 19 2.8k 1.5× 1.1k 0.7× 1.6k 1.4× 823 1.3× 1.0k 1.7× 37 5.7k
Saverio Cinieri Italy 32 2.5k 1.4× 1.0k 0.6× 930 0.8× 957 1.5× 230 0.4× 206 4.3k
Xavier Paolettí France 37 1.4k 0.8× 698 0.4× 707 0.6× 685 1.1× 618 1.0× 158 4.1k

Countries citing papers authored by Lisa Wang

Since Specialization
Citations

This map shows the geographic impact of Lisa Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lisa Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lisa Wang more than expected).

Fields of papers citing papers by Lisa Wang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lisa Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lisa Wang. The network helps show where Lisa Wang may publish in the future.

Co-authorship network of co-authors of Lisa Wang

This figure shows the co-authorship network connecting the top 25 collaborators of Lisa Wang. A scholar is included among the top collaborators of Lisa Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lisa Wang. Lisa Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Liu, Ruishan, Shemra Rizzo, Lisa Wang, et al.. (2024). Characterizing mutation-treatment effects using clinico-genomics data of 78,287 patients with 20 types of cancers. Nature Communications. 15(1). 10884–10884.
2.
Madariaga, Ainhoa, et al.. (2024). HER2-low and Overexpression in Mucinous Ovarian Cancer: Analysis of ASCO/CAP and ToGA Immunohistochemical Scoring. International Journal of Gynecological Pathology. 43(3). 275–283. 2 indexed citations
3.
Wang, Lisa & Akihiro Nakamura. (2024). Where are we in targeting hypoxia-induced pathways in inflammatory arthritis? Current understanding, insights, and future directions. International Immunopharmacology. 146. 113883–113883.
4.
Plante, Marie, Nienke E. van Trommel, Amit M. Oza, et al.. (2022). 2022-RA-678-ESGO CONTESSA/NEOCON-F trial: Assessing the effectiveness and safety of neoadjuvant chemotherapy followed by fertility-sparing surgery in FIGO 2018 stage IB2 cervical cancer. International Journal of Gynecological Cancer. 32. A20–A20.
5.
Johnson, Radia Marie, Xueping Qu, Ling‐Yuh Huw, et al.. (2022). ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer. Nature Communications. 13(1). 5478–5478. 24 indexed citations
6.
Doherty, Mark, Vincent C. Tam, Mairéad G. McNamara, et al.. (2022). Randomised, Phase II study of selumetinib, an oral inhibitor of MEK, in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer. British Journal of Cancer. 127(8). 1473–1478. 7 indexed citations
7.
Lee, Yeh Chen, Hao‐Wen Sim, Tanya Chawla, et al.. (2022). Interobserver and intraobserver variability of RECIST assessment in ovarian cancer. International Journal of Gynecological Cancer. 32(5). 656–661. 7 indexed citations
8.
Veitch, Zachary, Daniel Shepshelovich, Lisa Wang, et al.. (2021). Underreporting of Symptomatic Adverse Events in Phase I Clinical Trials. JNCI Journal of the National Cancer Institute. 113(8). 980–988. 40 indexed citations
9.
Madariaga, Ainhoa, Qin Liu, Luisa Bonilla, et al.. (2021). Ethical frameworks in clinical research processes during COVID-19: a scoping review. BMJ Open. 11(7). e047076–e047076. 6 indexed citations
10.
11.
Chen, Lina, Lisa Wang, Anna Spreafico, et al.. (2019). Characterization and outcomes of patients enrolled to multiple phase I cancer trials. Cancer Chemotherapy and Pharmacology. 85(2). 469–472. 1 indexed citations
12.
Wang, Lisa, et al.. (2017). Learning to Represent Student Knowledge on Programming Exercises Using Deep Learning.. Educational Data Mining. 34 indexed citations
13.
McWhirter, Elaine, Ian Quirt, Thomas F. Gajewski, et al.. (2016). A phase II study of cediranib, an oral VEGF inhibitor, in previously untreated patients with metastatic or recurrent malignant melanoma. Investigational New Drugs. 34(2). 231–235. 7 indexed citations
14.
15.
Tang, Patricia A., Steven J. Cohen, Christian Kollmannsberger, et al.. (2012). Phase II Clinical and Pharmacokinetic Study of Aflibercept in Patients with Previously Treated Metastatic Colorectal Cancer. Clinical Cancer Research. 18(21). 6023–6031. 67 indexed citations
16.
Puig, Noemí, Lisa Wang, Tara Seshadri, et al.. (2012). Treatment response and overall outcome of patients with relapsed and refractory peripheral T-cell lymphoma compared to diffuse large B-cell lymphoma. Leukemia & lymphoma. 54(3). 507–513. 6 indexed citations
17.
Stathis, Anastasios, Sébastien J. Hotte, Eric X. Chen, et al.. (2011). Phase I Study of Decitabine in Combination with Vorinostat in Patients with Advanced Solid Tumors and Non-Hodgkin's Lymphomas. Clinical Cancer Research. 17(6). 1582–1590. 79 indexed citations
18.
Baptista, João Pedro, Andrew Udy, Eduardo Sousa, et al.. (2011). A comparison of estimates of glomerular filtration in critically ill patients with augmented renal clearance. Critical Care. 15(3). R139–R139. 155 indexed citations
19.
Sridhar, Srikala S., Christina M. Canil, Kim N., et al.. (2010). A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer. Cancer Chemotherapy and Pharmacology. 67(4). 927–933. 21 indexed citations
20.
Lubner, Meghan G., et al.. (2007). Blood in the Belly: CT Findings of Hemoperitoneum. Radiographics. 27(1). 109–125. 122 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ali Shamseddine Breakdown of academic impact, for papers by Ondřej Topolčan Breakdown of academic impact, for papers by David S. Mendelson Breakdown of academic impact, for papers by Teresa A. Goldin Breakdown of academic impact, for papers by Madappa N. Kundranda Breakdown of academic impact, for papers by Recinda Sherman Breakdown of academic impact, for papers by Francesco Perrone Breakdown of academic impact, for papers by Stefano Rosso Breakdown of academic impact, for papers by Saverio Cinieri Breakdown of academic impact, for papers by Xavier Paolettí
Rankless by CCL
2026